Glycine Treatment of Prodromal Symptoms

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Stanley Medical Research Institute
• Treatments: Glycine

Criteria

Inclusion Criteria:

• age 14-35

• meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

• current antipsychotic medication

• more than 4 weeks of antipsychotic medication lifetime